@article {198175,
	title = {Tumor microenvironment-targeted nanoparticles loaded with bortezomib and ROCK inhibitor improve efficacy in multiple myeloma.},
	journal = {Nature communications},
	volume = {11},
	year = {2020},
	pages = {6037},
	abstract = {<p>Drug resistance and dose-limiting toxicities are significant barriers for treatment of multiple myeloma (MM). Bone marrow microenvironment (BMME) plays a major role in drug resistance in MM. Drug delivery with targeted nanoparticles have been shown to improve specificity and efficacy and reduce toxicity. We aim to improve treatments for MM by (1) using nanoparticle delivery to enhance efficacy and reduce toxicity; (2) targeting the tumor-associated endothelium for specific delivery of the cargo to the tumor area, and (3) synchronizing the delivery of chemotherapy (bortezomib; BTZ) and BMME-disrupting agents (ROCK inhibitor) to overcome BMME-induced drug resistance. We find that targeting the BMME with P-selectin glycoprotein ligand-1 (PSGL-1)-targeted BTZ and ROCK inhibitor-loaded liposomes is more effective than free drugs, non-targeted liposomes, and single-agent controls and reduces severe BTZ-associated side effects. These results support the use of PSGL-1-targeted multi-drug and even non-targeted liposomal BTZ formulations for the enhancement of patient outcome in MM.</p>
},
	author = {Federico, Cinzia and Alhallak, Kinan and Sun, Jennifer and Duncan, Kathleen and Azab, Feda and Sudlow, Gail P and de la Puente, Pilar and Muz, Barbara and Kapoor, Vaishali and Zhang, Luna and Yuan, Fangzheng and Markovic, Matea and Kotsybar, Joseph and Wasden, Katherine and Guenthner, Nicole and Gurley, Shannon and King, Justin and Kohnen, Daniel and Noha N. Salama and Thotala, Dinesh and Hallahan, Dennis E and Vij, Ravi and DiPersio, John F and Achilefu, Samuel and Azab,  Abdel Kareem}
}
